Patents Assigned to Mural Oncology, Inc.
  • Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy
    Publication number: 20250000938
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Application
    Filed: May 10, 2024
    Publication date: January 2, 2025
    Applicant: Mural Oncology, Inc.
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
  • Immunomodulatory Il-2 Agents in Combination With Immune Checkpoint Inhibitors
    Publication number: 20240352125
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Application
    Filed: April 1, 2024
    Publication date: October 24, 2024
    Applicant: Mural Oncology, Inc.
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • Compositions and methods for subcutaneous administration of cancer immunotherapy
    Patent number: 11980652
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: May 14, 2024
    Assignee: Mural Oncology, Inc.
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
  • Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
    Patent number: 11945870
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: April 2, 2024
    Assignee: Mural Oncology, Inc.
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist